与高剂量阿托瓦斯塔丁相关的拉布地质溶解:一个案例报告
Mrutyunjaya Behera1, Priyadarsi Tripathy2
1Ex-Professor and HOD, Department of Cardiology, SCB Medical College & Hospital, Cuttack, Odisha, India, Corresponding Author.
The Journal of the Association of Physicians of India
|September 16, 2025
概括
高剂量的阿托瓦斯塔丁可以导致严重的肌肉衰竭,严重的肌肉衰竭. 这一案例凸显了监测他类药物治疗的必要性,特别是在高剂量时,以防止潜在的致命结果,如急性损伤.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 与他类药物相关的肌肉损伤,包括神经分裂,是已知的不良影响.
- 高强度的他类药物治疗通常用于心血管疾病管理.
研究的目的:
- 在接受高剂量阿托瓦斯塔丁治疗的患者中报告严重的狂犬病和急性功能停止的病例.
- 为了强调与高剂量他类药物使用相关的潜在风险.
主要方法:
- 一个60岁的女性患者的病例报告介绍.
- 临床评估包括肌肉疼痛,软弱和疲劳的症状.
- 实验室调查显示了极高的肌酸化酶水平 (36,210 U/L).
- 治疗包括液体复苏,电解质校正和血液透析.
主要成果:
- 患者患有严重的狂犬病和急性功能停止,这归因于高剂量阿托瓦斯塔丁 (每天80毫克).
- 尽管进行了包括血液透析在内的密集治疗,但功能没有得到改善.
- 这位患者在住院15天后死于拉布多溶解的并发症.
结论:
- 高剂量的阿托瓦斯塔丁可以导致危及生命的狂犬病溶解和随后的急性损伤.
- 警监测他类药物诱导的肌肉病变至关重要,特别是在高强度疗法中.
- 这一案例强调了风险-益处评估在高剂量他类药物治疗中的重要性.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Renal Failure: Dose Adjustments
438
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
438
Acute Kidney Injury III: Clinical Manifestations
827
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
827
Acute Kidney Injury IV: Diagnostic Studies and Prevention
271
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
271
Chronic Kidney Disease II: Clinical Manifestations
557
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
557
Anticholinesterase Agents: Poisoning and Treatment
1.5K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.5K

